Drugs / WVE-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05032196 | Sep 2021 → May 2024 | Huntington disease | Wave Life Sciences USA, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WVE-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05032196 ↗ |
| Action | Inhibit | “Selective lowering of mHTT for the treatment of HD may provide a benefit over nonselective HTT-lowering approaches” PMID 39027419 ↗ Jun 2024 |
| Modality | Antisense oligonucleotide | “allele-selective stereopure antisense oligonucleotide (ASO)” NCT05032196 ↗ |
| Route | Intrathecal | “WVE-003 Administered Intrathecally” NCT05032196 ↗ |
| Target | HTT | “Selective lowering of mHTT for the treatment of HD may provide a benefit over nonselective HTT-lowering approaches” PMID 39027419 ↗ Jun 2024 |